Druker Brian — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Druker Brian has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Brian J. Druker is an American physician-scientist and oncology researcher widely recognized for leading the development of imatinib (Gleevec), a pioneering targeted therapy for chronic myeloid leukemia. He has long been associated with Oregon Health & Science University as the director of the Knight Cancer Institute and a leader in translational cancer research. According to the most recent SEC filing dated May 21, 2026, he serves as a director on the board of Amgen Inc.
Brian J. Druker is an American physician-scientist and oncology researcher widely recognized for leading the development of imatinib (Gleevec), a pioneering targeted therapy for chronic myeloid leukemia. He has long been associated with Oregon Health & Science University as the director of the Knight Cancer Institute and a leader in translational cancer research. According to t…
How many SEC Form 4 filings has Druker Brian submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Druker Brian's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
